Apoptotic capacity and risk of squamous cell carcinoma of the head and neck
Erich M. Sturgis(Baylor College of Medicine), José P. Zevallos(University of Pittsburgh Medical Center), Qingyi Wei(Hainan Normal University), Zhensheng Liu(Anhui Provincial Children's Hospital), Kouros Owzar(Duke University), Guojun Li(Ministry of Education of the People's Republic of China), Kristina R. Dahlstrom(Baylor College of Medicine), Fengqin Gao(The University of Texas MD Anderson Cancer Center), Hongliang Liu(Fosun Pharma (China))
Cited by 1
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Detectable clonal mosaicism from birth to old age and its relationship to cancer
|Nature Genetics|2012|598